GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval in two respiratory indications on the back of new phase 3 data showing the antibody improved disease symptoms and quality of life in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).